The headache field advances rapidly. Here are the key updates as of 2026 that actually matter for patients.
1. CGRP Antibodies — 5-Year Safety Data
~7 years since Aimovig, Ajovy, and Emgality launched. New 5-year follow-up data confirms no long-term safety concerns and maintained efficacy. Directly addresses patient worry about taking a newer drug long-term.
2. New Gepants Coming Soon
Oral CGRP antagonists rimegepant and atogepant already in use in the US and Europe. Insurance coverage discussions ongoing in Korea; expected 2026–2027. Key alternative for cardiovascular patients who cannot use triptans.
3. Magnesium — Meta-Analysis Reconfirms Benefit
Two 2024–2025 meta-analyses confirm magnesium supplementation reduces migraine frequency by 30–40% in deficient patients. Now AHS Level A evidence.
4. AHS Guidelines Updated
CGRP antibodies elevated to first-line preventive therapy. Low-dose aspirin recommended for menstrual migraine.
5. Digital Therapeutics
App-based biofeedback and CBT received FDA Breakthrough Device designation. Trials show meaningful reduction in monthly headache days.